Nigel Mackman

Summary

Publications

  1. pmc The role of tissue factor and factor VIIa in hemostasis
    Nigel Mackman
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599 7035, USA
    Anesth Analg 108:1447-52. 2009
  2. pmc Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease
    Pichika Chantrathammachart
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, NC 27599, USA
    Blood 120:636-46. 2012
  3. pmc Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin
    A Phillip Owens
    Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Clin Invest 122:558-68. 2012
  4. pmc Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer
    Jian guo Wang
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Blood 119:5543-52. 2012
  5. doi Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity
    Jeremiah C Boles
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Thromb Res 129:197-203. 2012
  6. pmc Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice
    Rafal Pawlinski
    Hematology and Oncology Division, Department of Medicine, University of North Carolina at Chapel Hill, NC, USA
    Blood 116:806-14. 2010
  7. pmc Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease
    Erica M Sparkenbaugh
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
    Blood 123:1747-56. 2014
  8. pmc PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI
    Raj S Kasthuri
    Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Blood 119:5285-93. 2012
  9. pmc Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies
    Surya V Seshan
    Department of Pathology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
    Blood 114:1675-83. 2009
  10. pmc Tissue factor and thrombosis: The clot starts here
    A Phillip Owens
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, USA
    Thromb Haemost 104:432-9. 2010

Collaborators

Detail Information

Publications39

  1. pmc The role of tissue factor and factor VIIa in hemostasis
    Nigel Mackman
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599 7035, USA
    Anesth Analg 108:1447-52. 2009
    ..However, the mechanism by which recombinant FVIIa restores hemostasis has not been clearly defined. In conclusion, the TF:FVIIa complex is essential for hemostasis and recombinant FVIIa is an effective hemostatic drug...
  2. pmc Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease
    Pichika Chantrathammachart
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, NC 27599, USA
    Blood 120:636-46. 2012
    ..Furthermore, it appears that TF contributes to these processes without affecting intravascular hemolysis...
  3. pmc Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin
    A Phillip Owens
    Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Clin Invest 122:558-68. 2012
    ..Our results suggest that the prothrombotic state associated with hypercholesterolemia is caused by oxLDL-mediated induction of TF expression in monocytes via engagement of a TLR4/TLR6 complex...
  4. pmc Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer
    Jian guo Wang
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Blood 119:5543-52. 2012
    ..The results of the present study using a xenograft mouse model suggest that tumor TF activates coagulation, whereas TF on circulating MPs may trigger venous thrombosis...
  5. doi Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity
    Jeremiah C Boles
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Thromb Res 129:197-203. 2012
    ..Malignancy conveys an increased risk for thrombosis and chemotherapy further elevates this risk. The pathophysiological mechanisms underlying this process remain poorly defined...
  6. pmc Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice
    Rafal Pawlinski
    Hematology and Oncology Division, Department of Medicine, University of North Carolina at Chapel Hill, NC, USA
    Blood 116:806-14. 2010
    ..Our data demonstrate that in a mouse model of endotoxemia activation of the coagulation cascade is initiated by TF expressed by myeloid cells and an unidentified nonhematopoietic cell type(s)...
  7. pmc Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease
    Erica M Sparkenbaugh
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
    Blood 123:1747-56. 2014
    ..Our data indicate that TF, FXa, and thrombin differentially contribute to vascular inflammation in a mouse model of SCD. ..
  8. pmc PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI
    Raj S Kasthuri
    Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Blood 119:5285-93. 2012
    ..Our data suggest that monocyte TF may contribute to the development of thrombosis in patients with HIT...
  9. pmc Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies
    Surya V Seshan
    Department of Pathology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
    Blood 114:1675-83. 2009
    ..Treatment with pravastatin, which down-regulates glomerular TF synthesis, prevents aPL-induced TMA in this mouse model, thus emphasizing that targeting TF might be a good therapeutic intervention in patients with TMA...
  10. pmc Tissue factor and thrombosis: The clot starts here
    A Phillip Owens
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, USA
    Thromb Haemost 104:432-9. 2010
    ..Understanding the role of TF in thrombosis may permit the development of new antithrombotic drugs. This review will focus on the role of TF in in vivo models of thrombosis...
  11. pmc Multiple roles of the coagulation protease cascade during virus infection
    Silvio Antoniak
    Thrombosis and Hemostasis Program, Division of Hematology and Oncology, Department of Medicine, University of North Carolina McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC
    Blood 123:2605-13. 2014
    ..These studies indicate that the coagulation cascade plays multiple roles during viral infections...
  12. ncbi Role of tissue factor in atherothrombosis
    A Phillip Owens
    Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, 98 Manning Drive Campus Box 7035, Chapel Hill, NC 27599, USA
    Curr Atheroscler Rep 14:394-401. 2012
    ..In addition, currently used therapeutics, such as statins and inhibitors of the renin angiotensin system, may have additional benefits by reducing TF expression and subsequent thrombosis...
  13. pmc PAR-1 contributes to the innate immune response during viral infection
    Silvio Antoniak
    Department of Medicine, Division of Hematology and Oncology, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Clin Invest 123:1310-22. 2013
    ..Our results indicate that the tissue factor/thrombin/PAR-1 pathway enhances IFN-β expression and contributes to the innate immune response during single-stranded RNA viral infection...
  14. doi Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation
    Ilene C Weitz
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles 90033, CA, USA
    Thromb Res 130:361-8. 2012
    ....
  15. pmc Platelet ITAM signaling is critical for vascular integrity in inflammation
    Yacine Boulaftali
    McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Clin Invest 123:908-16. 2013
    ....
  16. pmc Microparticles in hemostasis and thrombosis
    A Phillip Owens
    Division of Hematology Oncology, Department of Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, North Carolina, USA
    Circ Res 108:1284-97. 2011
    ..This review will summarize our current knowledge of the role of procoagulant MPs in hemostasis and thrombosis...
  17. pmc Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays
    Raj S Kasthuri
    Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Semin Thromb Hemost 36:764-71. 2010
    ..Therefore, there is a need to develop sensitive and specific assays for measuring levels of functional TF and TFPI in whole blood and plasma. These assays could be useful in patient management in many scenarios...
  18. pmc Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury
    Silvio Antoniak
    Division of Hematology Oncology, Department of Medicine, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
    Arterioscler Thromb Vasc Biol 30:2136-42. 2010
    ..To investigate the effect of protease-activated receptor (PAR) 2 deficiency on ischemia/reperfusion (I/R) injury-induced infarct size, inflammation, heart remodeling, and cardiac function...
  19. pmc Protease activated receptor-2 contributes to heart failure
    Silvio Antoniak
    UNC McAllister Heart Institute, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 8:e81733. 2013
    ..Taken together, our data indicate that PAR-2 signaling contributes to the pathogenesis of hypertrophy and heart failure. ..
  20. pmc New insights into the mechanisms of venous thrombosis
    Nigel Mackman
    Division of Hematology Oncology, Department of Medicine, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Invest 122:2331-6. 2012
    ..Subsequent activation of the leukocytes induces expression of the potent procoagulant protein tissue factor that triggers thrombosis. Understanding the mechanisms of venous thrombosis may lead to the development of new treatments...
  21. pmc Role of tissue factor in cancer
    Raj S Kasthuri
    Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 27:4834-8. 2009
    ..Nevertheless, additional studies are needed to determine if this strategy can be successfully translated to the treatment of cancer patients...
  22. pmc Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism
    David A Manly
    Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
    Thromb Res 125:511-2. 2010
    ..7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE...
  23. doi Microvesicles as risk markers for venous thrombosis
    Pierre Emmanuel Rautou
    Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, 27599, USA
    Expert Rev Hematol 6:91-101. 2013
    ..However, further studies are needed to determine if TF-positive MVs are a good biomarker for venous thrombosis in cancer and other diseases...
  24. doi Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque
    A Phillip Owens
    Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, 98 Manning Drive Campus Box 7035, Chapel Hill, NC 27599, USA
    Thromb Res 129:S30-3. 2012
    ..This review will summarize the connections between hyperlipidemia and TF expression within atherosclerotic plaques and circulating monocytes, as well as its inhibition by statins...
  25. pmc Protease-activated receptors and myocardial infarction
    Silvio Antoniak
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    IUBMB Life 63:383-9. 2011
    ..These discrepant results between genetic and pharmacological approaches indicate that further studies are needed to determine the role of different PARs in the injured heart...
  26. pmc Cellular sources of tissue factor in endotoxemia and sepsis
    Rafal Pawlinski
    Hematology and Oncology Division, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA
    Thromb Res 125:S70-3. 2010
    ..This review focuses on tissue factor expression by hematopoietic and non-hematopoietic cells and its contribution to the activation of coagulation during endotoxemia and sepsis...
  27. pmc Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner
    Jian guo Wang
    Division of Hematology and Oncology, Department of Medicine, McAllister Heart Institute, Chapel Hill, NC, USA
    Blood 118:2366-74. 2011
    ..Therefore, monocytic MPs contain IL-1β and may amplify inflammation by enhancing the activation of the endothelium...
  28. ncbi Tissue factor in health and disease
    Julie C Williams
    Division of Hematology and Oncology, Department of Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, North Carolina, USA
    Front Biosci (Elite Ed) 4:358-72. 2012
    ..Pathologic TF expression is found in patients with a number of different diseases. This review will describe the roles of TF in health and disease as well as discuss approaches to reduce pathologic TF expression...
  29. doi Tissue factor and its measurement in whole blood, plasma, and microparticles
    Nigel S Key
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Semin Thromb Hemost 36:865-75. 2010
    ..We comment on some of the crucial preanalytical and analytical variables that influence the results and their interpretation...
  30. pmc Triggers, targets and treatments for thrombosis
    Nigel Mackman
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Nature 451:914-8. 2008
    ..The pathogenic changes that occur in the blood vessel wall and in the blood itself resulting in thrombosis are not fully understood. Understanding these processes is crucial for developing safer and more effective antithrombotic drugs...
  31. pmc Effect of PAR-2 Deficiency in Mice on KC Expression after Intratracheal LPS Administration
    Julie C Williams
    Division of Hematology and Oncology, Department of Medicine, McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
    J Signal Transduct 2011:415195. 2011
    ..Infiltration of neutrophils and macrophages into the lung following LPS administration was not affected by an absence of PAR-2. Our results support the notion that PAR-2 plays a role in LPS activation of TLR4 signaling in macrophages...
  32. pmc New players in haemostasis and thrombosis
    Julia E Geddings
    Nigel Mackman, PhD, Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA, Tel 1 919 843 3961, Fax 1 919 966 7639, E mail
    Thromb Haemost 111:570-4. 2014
    ..NETs can capture platelets and increase fibrin deposition. The recent advances in our understanding of the factors contributing to thrombosis in animal models provide new opportunities for the development of safer anticoagulant drugs. ..
  33. pmc Coagulation, protease-activated receptors, and viral myocarditis
    Silvio Antoniak
    Division of Hematology and Oncology, Department of Medicine, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, 98 Manning Drive, Campus Box 7035, Chapel Hill, NC, 27599, USA
    J Cardiovasc Transl Res 7:203-11. 2014
    ..These observations suggest that anticoagulants may impair the innate immune response to viral infection and that inhibition of PAR-2 may be a new strategy to reduce viral myocarditis. ..
  34. pmc Roles of PAR1 and PAR2 in viral myocarditis
    Nigel Mackman
    Department of Medicine, Division of Hematology and Oncology, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, 98 Manning Drive Campus Box 7035, Chapel Hill, NC, USA Electronic address
    Thromb Res 133:S18-20. 2014
    ..Our studies support the notion that PARs modulate the innate immune response and can have both positive and negative effects on TLR-dependent responses. ..
  35. doi The antithrombotic effects of statins
    A Phillip Owens
    Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 email
    Annu Rev Med 65:433-45. 2014
    ..These antithrombotic activities of statins likely contribute to the ability of statins to reduce the incidence of cardiovascular death. ..
  36. ncbi Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis
    Noppacharn Uaprasert
    Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Eur J Cancer 46:1790-9. 2010
    ..These studies may not only yield greater insight into the pathogenesis of disease but may also define novel targets for the prevention and treatment of thromboembolic events in patients with multiple myeloma...
  37. pmc Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury
    Patricia Redecha
    Hospital for Special Surgery, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 110:2423-31. 2007
    ..The identification of TF as an important mediator of C5a-induced oxidative burst in neutrophils in aPL-induced fetal injury provides a new target for therapy to prevent pregnancy loss in the antiphospholipid syndrome...
  38. ncbi Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 26:682-8. 2005
    ..Sunol-cH36, a chimaeric monoclonal antibody to TF, blocks binding of factor X to the TF:VIIa complex. This report describes the first completed trial of Sunol-cH36 in humans...
  39. ncbi Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1
    Udo Bavendiek
    Leducq Center for Cardiovascular Research, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:25032-9. 2002
    ....